Schonfeld Strategic Advisors 13F: Adds $8M to ALNY Stake

Schonfeld Expands Position in Alnylam

Schonfeld Strategic Advisors increased its investment in Alnylam Pharmaceuticals, Inc. (NasdaqGS: ALNY) during the period ended May 15, 2026, according to a Form 13F filing with the Securities and Exchange Commission. The fund picked up 26,873 extra shares, lifting its total holdings to 71,767 shares. This report looks backward at portfolio choices made as of May 15, 2026, and may not reflect the investor's current position today.

Details of the Portfolio Move

The fund grew its stake by 59.8% compared to its prior count of 44,894 shares. The newly expanded holding carried a reported value of roughly $21.4 million. This transaction follows other portfolio adjustments by institutional investors in the same equity, as larger funds actively reshape their biotechnology holdings.

Alnylam Shares Trade Near Midpoint

The biotechnology equity changed hands around $298.10 on Saturday, resting well away from its 52-week low of $197.81 and its 52-week high of $495.55. The company carries a trailing price-to-earnings ratio of 42.49 alongside a forward P/E ratio of 19.59.

Strong Financial Results Back Recent Growth

Alnylam reported $4.8 billion in trailing revenue with a revenue growth rate of 66.9%. The enterprise posted net income margins of 16.1% and a return on equity of 96.6%. The next earnings release is scheduled for October 29, 2026.

Wall Street Analyst Outlook

Financial firms continue to update their views on the therapeutics developer. On October 14, 2026, Citigroup maintained a buy rating while moving its target to $320.00 from $340.00. On the same day, Wells Fargo kept an equal-weight rating with a $253.00 target, down from $256.00. Earlier in October, RBC Capital maintained an outperform rating with a $345.00 target, moving down from $350.00. JP Morgan maintained an overweight rating on September 30, 2026, setting a target of $369.00. HC Wainwright & Co. reiterated a buy rating on September 21, 2026, with a target of $455.00. Jefferies kept a hold rating on September 8, 2026, raising its target to $260.00 from $230.00. BMO Capital initiated coverage on August 19, 2026, with an outperform rating and a $318.00 target.

Inside Alnylam's Therapeutics Pipeline

Alnylam Pharmaceuticals discovers and commercializes ribonucleic acid interference treatments for rare conditions, including ONPATTRO and AMVUTTRA for amyloidosis, GIVLAARI for acute hepatic porphyria, and Leqvio for cholesterol management. The enterprise runs an active clinical pipeline spanning Phase 1, Phase 2, and Phase 3 trials across multiple therapeutic categories.

What to Watch at Alnylam Pharmaceuticals, Inc.

Investors will monitor upcoming regulatory updates and the company's next earnings report on October 29, 2026, to gauge pipeline progress. Future Form 13F filings will reveal whether Schonfeld and other institutional managers continue adding to or reducing their stakes.